An “enforcement discretion” policy
According to the published policy, the FDA will not take action against compounders making the six peptides if they meet specific requirements. The key points are:
- The six peptides covered are BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax, which are promoted for uses ranging from tissue repair and inflammation to sleep and chronic pain.
- Compounders must meet requirements on ingredient quality, manufacturing standards, safety reporting and labelling.
- Products may only be compounded under patient-specific prescriptions.
The department said it may reconsider the policy if safety signals or product-quality problems emerge.
















